Lyudmila A. Bazhenova
University of California San Diego · 583 works · 18,906 citations · h-index 60
Top works
- Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
- Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials
- NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 4.2016
- Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study
- Trastuzumab Deruxtecan in HER2 -Mutant Non–Small-Cell Lung Cancer
- Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer
- Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRAS G12C Mutation
- Non–Small Cell Lung Cancer, Version 6.2015
- Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial
- 1372P Repotrectinib in patients (pts) with NTRK fusion-positive (NTRK+) advanced solid tumors, including NSCLC: Update from the phase I/II TRIDENT-1 trial
- CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials
- Molecular Tumor Board: The University of California San Diego Moores Cancer Center Experience
- A Phase II Study of PD-0325901, an Oral MEK Inhibitor, in Previously Treated Patients with Advanced Non–Small Cell Lung Cancer
- Fluid biopsy in patients with metastatic prostate, pancreatic and breast cancers
- Analysis of NTRK Alterations in Pan-Cancer Adult and Pediatric Malignancies: Implications for NTRK-Targeted Therapeutics
- Precision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience
- Characterization of circulating tumor cell aggregates identified in patients with epithelial tumors
- Non–Small Cell Lung Cancer, Version 1.2015
- First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRAS G12C Solid Tumors (KRYSTAL-1)
- Rapid and Dramatic Radiographic and Clinical Response to an ALK Inhibitor (Crizotinib, PF02341066) in an ALK Translocation-Positive Patient with Non-small Cell Lung Cancer